| Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells. | |
| | |
MedLine Citation:
|
PMID: 23225424 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Cholangiocarcinoma (CCC) is the second most common type of primary liver cancer, and is associated with a high rate of mortality due to the difficulty of early detection and resistance to chemotherapeutic agents. To evaluate the possibility for new therapeutic strategies, we examined the combined effect of gefitinib and gemcitabine on CCC. MATERIALS AND METHODS: The effect of gefitinib, an inhibitor of epidermal growth factor receptor (EGFR) signaling, gemcitabine, which is a pyrimidine analog, and the combined effect of gefitinib and gemcitabine on CCC cells were evaluated both in vitro and in vivo. RESULTS: EGFR mRNA expression and phosphorylation of EGFR were elevated in both human CCC cell lines studied, HuCCT1 and RBE, suggesting EGFR signaling is up-regulated in CCC cell lines. Gefitinib treatment at high concentration inhibited the proliferation of the CCC cell lines. Furthermore, gefitinib reduced the transforming growth factor alpha (TGFα)-induced proliferation of these cells. Gemcitabine also suppressed the growth of the CCC cell lines in a concentration-dependent manner. The combination of gefitinib and gemcitabine synergistically suppressed the growth of the CCC cell lines and induced greater apoptosis compared to the use of either agent alone. As a mechanism for this effect, we found less phosphorylation of the extracellular signal-regulated kinase (ERK) protein, which means the suppression of EGFR signaling, when these compounds were administered together. Cell transplantation assay dramatically demonstrated the synergistic effect of this combination on HuCCT1 xenografts in vivo. CONCLUSION: The combination of gefitinib and gemcitabine inhibited the proliferation of CCC cells via induction of apoptosis. The combination of EGFR inhibitor and additional chemicals could be a new therapeutic approach for CCC. |
| | |
Authors:
|
Yoshimi Nakajima; Hitoshi Takagi; Satoru Kakizaki; Norio Horiguchi; Ken Sato; Noriaki Sunaga; Masatomo Mori |
Related Documents
:
|
21276094 - Multiple effects of benzamide antibiotics on ftsz function. 22402744 - Pleiotropic effects of mir-183~96~182 converge to regulate cell survival, proliferation... 23533514 - Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy... 23434674 - Modified pamam dendrimer with 4-carbomethoxypyrrolidone surface groups reveals negligib... 7963724 - The extent of human cytomegalovirus replication in primary neurons is dependent on host... 2085794 - Formation of genotoxic products from n-nitrosoheptamethyleneimine (nhmi), 4-(methylnitr... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Anticancer research Volume: 32 ISSN: 1791-7530 ISO Abbreviation: Anticancer Res. Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-12-10 Completed Date: 2013-05-02 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 8102988 Medline TA: Anticancer Res Country: Greece |
Other Details:
|
Languages: eng Pagination: 5251-62 Citation Subset: IM |
Affiliation:
|
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Combined Chemotherapy Protocols / pharmacology* Bile Duct Neoplasms / drug therapy*, metabolism, pathology Bile Ducts, Intrahepatic / metabolism, pathology Carcinoma, Non-Small-Cell Lung / drug therapy, metabolism, pathology Cell Growth Processes / drug effects Cell Line, Tumor Cholangiocarcinoma / drug therapy*, metabolism, pathology Deoxycytidine / administration & dosage, analogs & derivatives*, pharmacology Hep G2 Cells Humans Liver Neoplasms / drug therapy, metabolism, pathology Lung Neoplasms / drug therapy, metabolism, pathology Mice Mice, Nude Quinazolines / administration & dosage, pharmacology* Random Allocation Receptor, Epidermal Growth Factor / metabolism Signal Transduction / drug effects Xenograft Model Antitumor Assays |
| Chemical | |
Reg. No./Substance:
|
0/Quinazolines; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine; EC 2.7.10.1/Receptor, Epidermal Growth Factor; S65743JHBS/gefitinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expression of E-Cadherin and ?-Catenin in T1 N0 Laryngeal Cancer.
Next Document: Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo.